Aduhelm™ (aducanumab-avwa) – Updated labeling
July 8, 2021 - Biogen announced the FDA approval of updated labeling for Aduhelm (aducanumab-avwa), emphasizing that Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia.
Download PDF
